TaiMed Biologics Inc (中裕新藥) yesterday said that it plans to market its Trogarzo HIV treatment in Germany by the end of this year, expressing confidence that it would obtain marketing approval from European regulators in October.
The European Medicines Agency’s (EMA) human medicines committee had a positive opinion on Trogarzo at a meeting on Friday last week, TaiMed chief financial officer Jack Chen (陳怡成) said.
That is important for TaiMed’s business in Europe, as the European Commission takes the committee’s recommendation into account when deciding on marketing approval for new treatments, Chen said.
“If everything goes smoothly, it is likely that we will receive marketing approval in early October,” Chen said.
TaiMed and its business partner, Canada-based Theratechnologies Inc, have decided that Germany would be Trogarzo’s first European market, he said.
Germany has a high income per capita and its regulations on drug prices are more friendly to pharmaceutical companies, he said.
Drug companies there can market their products before wholesale prices are finalized by the regulator, unlike other European markets, he added.
The price of Trogarzo is set at US$118,000 for a year of treatment in the US, but it is expected to fall by 25 to 35 percent in European markets, Chen said.
Theratechnologies, which helps sell Trogarzo in the US, would be responsible for negotiating the price with local regulatory bodies in Europe, he said.
As TaiMed did not conduct any clinical trials in Europe and used the data generated from its trials in the US for the European review, it is required by EMA to establish a mechanism to monitor local patients and to collect data, Chen said.
TaiMed has seen US sales of Trogarzo rise since the US Food and Drug Administration approved the treatment in March last year, he said.
The company posted cumulative revenue of NT$283 million (US$9.1 million) in the first half of this year, up 638 percent year-on-year, thanks to the rising sales of Trogarzo in the US, Chen said.
European sales are expected to boost whole-year revenue to about NT$800 million, he added.
Contract manufacturer WuXi Biologics Co (無錫生物製藥) would be responsible for the production of Trogarzo for European markets, as TaiMed’s new contract manufacturing partner Samsung BioLogics Co’s new plant in Hsinchu County’s Jhubei City (竹北) is still preparing for production, Chen said.
In the US clinical trial, Trogarzo was proven to have a long-lasting impact on HIV-1, with 83 percent of patients reducing their HIV-1 viral load after receiving a single dose of the drug, the company said.
POWERING UP: PSUs for AI servers made up about 50% of Delta’s total server PSU revenue during the first three quarters of last year, the company said Power supply and electronic components maker Delta Electronics Inc (台達電) reported record-high revenue of NT$161.61 billion (US$5.11 billion) for last quarter and said it remains positive about this quarter. Last quarter’s figure was up 7.6 percent from the previous quarter and 41.51 percent higher than a year earlier, and largely in line with Yuanta Securities Investment Consulting Co’s (元大投顧) forecast of NT$160 billion. Delta’s annual revenue last year rose 31.76 percent year-on-year to NT$554.89 billion, also a record high for the company. Its strong performance reflected continued demand for high-performance power solutions and advanced liquid-cooling products used in artificial intelligence (AI) data centers,
SIZE MATTERS: TSMC started phasing out 8-inch wafer production last year, while Samsung is more aggressively retiring 8-inch capacity, TrendForce said Chipmakers are expected to raise prices of 8-inch wafers by up to 20 percent this year on concern over supply constraints as major contract chipmakers Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and Samsung Electronics Co gradually retire less advanced wafer capacity, TrendForce Corp (集邦科技) said yesterday. It is the first significant across-the-board price hike since a global semiconductor correction in 2023, the Taipei-based market researcher said in a report. Global 8-inch wafer capacity slid 0.3 percent year-on-year last year, although 8-inch wafer prices still hovered at relatively stable levels throughout the year, TrendForce said. The downward trend is expected to continue this year,
‘BASICALLY A BAN’: Sources said the wording governing H200 imports from officials was severe, but added that the regulations might change if the situation evolves Chinese customs authorities told customs agents this week that Nvidia Corp’s H200 artificial intelligence (AI) chips are not permitted to enter China, three people briefed on the matter said. Chinese government officials also summoned domestic technology companies to meetings on Tuesday, at which they were explicitly instructed not to purchase the chips unless necessary, two of the people and a third source said. “The wording from the officials is so severe that it is basically a ban for now, though this might change in the future should things evolve,” one of the people said. The H200, Nvidia’s second-most powerful AI chip, is one
A proposed billionaires’ tax in California has ignited a political uproar in Silicon Valley, with tech titans threatening to leave the state while California Governor Gavin Newsom of the Democratic Party maneuvers to defeat a levy that he fears would lead to an exodus of wealth. A technology mecca, California has more billionaires than any other US state — a few hundred, by some estimates. About half its personal income tax revenue, a financial backbone in the nearly US$350 billion budget, comes from the top 1 percent of earners. A large healthcare union is attempting to place a proposal before
RSS